Biosensors: Following a regulatory approval obtained in Aug-15, Biosensors announced that they will commercialize its BMX-J drug eluting stent (DES) system in Japan from 1 Oct 15.
The BMX-J is an OEM version of the Nobori DES, which includes a biodegradable polymer and Biosensors' proprietary drug, Biolimus A9.
OCBC understands that the technology is already well accepted by cardiologists in Japan. Keeping in mind that the contractual agreement between Biosensors and Terumo is slated to end in 2016, Biosensors has been expanding its distribution reach across Japan, and they will continue to expand their channels to increase coverage.
House maintains HOLD with TP of $0.63.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment